Ramucircumab is used in the treatment of :
**Core Concept**
Ramucirumab is a recombinant human monoclonal antibody that targets and inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), which is involved in angiogenesis. Inhibition of VEGFR-2 leads to reduced tumor growth and metastasis.
**Why the Correct Answer is Right**
Ramucirumab is used in the treatment of advanced gastric cancer and non-small cell lung cancer (NSCLC). It works by blocking the VEGF pathway, which is crucial for tumor angiogenesis. By inhibiting this pathway, ramucirumab reduces the formation of new blood vessels that supply the tumor with oxygen and nutrients. This, in turn, slows down tumor growth and progression.
**Why Each Wrong Option is Incorrect**
**Option A:** Ramucirumab is not used in the treatment of breast cancer. While it targets VEGFR-2, which is involved in angiogenesis, it is not the first-line treatment for breast cancer.
**Option B:** Bevacizumab is another monoclonal antibody that targets VEGF-A, not VEGFR-2, and is used in the treatment of various cancers, including colorectal, non-small cell lung, and breast cancer. Ramucirumab is specific to VEGFR-2.
**Option C:** Sunitinib is a tyrosine kinase inhibitor that targets multiple receptors, including VEGFR, PDGFR, and c-KIT. While it is used in the treatment of renal cell carcinoma and gastrointestinal stromal tumors, it is not the same as ramucirumab.
**Clinical Pearl / High-Yield Fact**
Ramucirumab is often used in combination with other chemotherapeutic agents, such as docetaxel, to enhance its efficacy in treating advanced gastric cancer and NSCLC.
**Correct Answer:** C.